BioDelivery Sciences International Inc.
801 Corporate Ceter Drive
Suite 210
Raleigh,
NC 27607
United States - Map
Phone: 919-582-9050
Fax: 919-582-9051
Web Site: http://www.bdsinternational.com
| BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The companys products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Mark A. Sirgo Ph.D.,
Chief Exec. Officer, Pres, Chief Scientific Officer and Exec. Director |
N/A
| N/A | Mr. James A. McNulty CPA,
Chief Financial Officer, Principal Accounting Officer, Sec. and Treasurer |
N/A
| N/A | Dr. Andrew L. Finn Pharm.D., 60
Exec. VP of Product Devel. |
N/A
| N/A | Mr. Donald L. Ferguson , 60
Sr. Exec. VP |
N/A
| N/A | Mr. Charles E. Dadswell Esq.,
Director of Contracts Management & Intellectual Property and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.28% Nasdaq 
Profile
